The Efficacy and Safety of Nirsevimab for the Prevention of RSV Infection Among Infants: A Systematic Review and Meta-Analysis
- Maria Turalde-Mapili; Jerahmeel Mapili; Christian Turalde; Marimel Pagcatipunan
Access Resources
About
This article describes a study on nirsevimab, a new drug to prevent RSV infections in infants. RSV is a virus that can cause serious lung problems in babies. The study shows that nirsevimab reduces the risk of RSV-related illnesses and hospital stays without increasing severe side effects. It compares two trials and finds differences based on whether infants were born early or full-term. While promising, more research is needed to understand its cost-effectiveness and potential risks for preterm babies. The study highlights the importance of keeping medical guidelines up-to-date with new evidence.
Tags
More like this
The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.